Grace Therapeutics Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage
DATE: | November 20, 2024 |
---|---|
TIME: | 2:00 PM EST |
LOCATION: | Virtual |
About The Event
Join Grace Therapeutics for a virtual KOL event, featuring Abhishek Ray, MD (University Hospitals) and Andrew Webb, PharmD, BCCCP (Massachusetts General Hospital), who will discuss the high unmet medical need and current treatment landscape for patients suffering from aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency.
The event will highlight the opportunity for Grace’s lead clinical asset, GTx-104, a novel injectable formulation of nimodipine that overcomes the challenges and limitations of orally administered standard of care. Grace Therapeutics recently announced completion of enrollment in its Phase 3 STRIVE-ON open-label safety trial evaluating GTx-104 for intravenous (IV) infusion in aSAH patients, with top-line data guided for early 2025.
A live question and answer session will follow the formal presentations.